These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 6527211)

  • 1. Similar effects of various low-molecular-weight enzyme inhibitors on enzyme networks in dystrophic mice.
    Aoyagi T; Wada T; Ohuchi S; Kojima F; Nagai M; Harada S; Umezawa H
    J Pharmacobiodyn; 1984 Sep; 7(9):681-7. PubMed ID: 6527211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multivariate study on enzymatic changes in limb muscles and heart muscle of dystrophic mice.
    Aoyagi T; Wada T; Kojima F; Nagai M; Harada S; Umezawa H
    Biotechnol Appl Biochem; 1987 Oct; 9(5):355-61. PubMed ID: 3675874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low molecular weight immunomodifiers produced by microorganisms.
    Umezawa H; Ishizuka M
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S9-13. PubMed ID: 3842696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationships between enzyme inhibitors and function of mammalian cells.
    Aoyagi T; Umezawa H
    Acta Biol Med Ger; 1981; 40(10-11):1523-9. PubMed ID: 7044007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relation between in vivo effects and in vitro effects of serine and thiol proteinase inhibitors.
    Aoyagi T; Wada T; Umezawa K; Kojima F; Nagai M; Umezawa H
    J Pharmacobiodyn; 1983 Sep; 6(9):643-53. PubMed ID: 6361230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic trial with protease inhibitor (leupeptin) in chicken muscular dystrophy. A histologic and histochemical study.
    Nonaka I; Ishiura S; Takagi A; Sugita H
    Acta Neuropathol; 1982; 58(4):279-85. PubMed ID: 7158305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-molecular-weight immunomodifiers produced by micro-organisms.
    Umezawa H
    Biotechnol Genet Eng Rev; 1985; 3():255-73. PubMed ID: 2936359
    [No Abstract]   [Full Text] [Related]  

  • 8. Difference in enzyme networks between mouse and hamster models of muscular dystrophy.
    Aoyagi T; Wada T; Yamamoto K; Kojima F; Nagai M; Umezawa H
    J Pharmacobiodyn; 1984 May; 7(5):312-21. PubMed ID: 6088754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different enzymatic oscillations in vivo caused by the stereoisomers of an aminopeptidase inhibitor, bestatin.
    Aoyagi T; Wada T; Yamamoto K; Kojima F; Nagai M; Harada S; Umezawa H
    J Appl Biochem; 1984 Aug; 6(4):212-21. PubMed ID: 6520072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oscillation of enzyme networks in spleen triggered by an immunopotentiator, bestatin.
    Aoyagi T; Wada T; Ohuchi S; Kojima F; Nagai M; Kawahara F; Umezawa H
    Biochem Int; 1984 Oct; 9(4):405-11. PubMed ID: 6097256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mode of action of bestatin and leupeptin to induce the accumulation of acid soluble peptides in rat liver in vivo and the properties of the accumulated peptides. The important role of bestatin- and leupeptin-sensitive proteases in the protein degradation pathway in vivo.
    Takahashi S; Kato H; Takahashi A; Noguchi T; Naito H
    Int J Biochem; 1987; 19(5):401-12. PubMed ID: 3595989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitogenic potentials of bestatin, amastatin, arphamenines A and B, FK-156 and FK-565 on spleen lymphocytes.
    Weissmann N; Leyhausen G; Maidhof A; Tanaka W; Umezawa H; Müller WE
    J Antibiot (Tokyo); 1985 Jun; 38(6):772-8. PubMed ID: 4019321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on low-molecular-weight immunomodifiers produced by microorganisms: results of ten years' effort.
    Umezawa H
    Rev Infect Dis; 1984; 6(3):412-20. PubMed ID: 6234644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymatic changes in dystrophic mice and their age dependency.
    Wada T; Aoyagi T
    Metabolism; 1983 Nov; 32(11):1076-80. PubMed ID: 6621365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of aminopeptidases by amastatin and bestatin derivatives. Effect of inhibitor structure on slow-binding processes.
    Rich DH; Moon BJ; Harbeson S
    J Med Chem; 1984 Apr; 27(4):417-22. PubMed ID: 6142952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo actions of bestatin-related compounds in relation to their actions in vitro.
    Aoyagi T; Wada T; Ohuchi S; Kawamura K; Fukatsu S; Umezawa H
    Biochem Int; 1984 Nov; 9(5):643-50. PubMed ID: 6525200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Various enzyme activities in muscle and other organs of dystrophic mice.
    Aoyagi T; Wada T; Kojima F; Nagai M; Umezawa H
    J Clin Invest; 1981 Jan; 67(1):51-9. PubMed ID: 6256414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leupeptin, a protease inhibitor, decreases protein degradation in normal and diseased muscles.
    Libby P; Goldberg AL
    Science; 1978 Feb; 199(4328):534-6. PubMed ID: 622552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular enzyme abnormalities of dystrophic chickens compared to those of dystrophic mice.
    Wada T; Kojima F; Nagai M; Aoyagi T; Umezawa H
    J Pharmacobiodyn; 1981 Mar; 4(3):184-90. PubMed ID: 7019413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dissociation of creatine kinase activity from hydrolytic enzyme activities in muscle of dystrophic mice.
    Aoyagi T; Wada T; Kojima F; Nagai M; Harada S; Saito M; Hioki K; Umezawa H
    Biochem Int; 1985 Oct; 11(4):541-9. PubMed ID: 4084316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.